The primary purpose of a business is to generate profits that can be reinvested in expansion or utilized for rewarding shareholders. Net profit margin is an effective tool to measure the profits reaped by a business.A higher net margin underlines a company’s efficiency in translating sales into actual profits. Moreover, this metric gives insight into how well a company is run and the headwinds weighing on it. Castle Biosciences, Inc. (CSTL) , OppFi, Inc. (OPFI) , GigaCloud Technology Inc. (GCT) and Qifu Tec ...

Investors seek companies that consistently generate profits. One of the best metrics to measure profitability is the net profit margin. This metric highlights a company's ability to convert sales into actual profits, providing insights into operational efficiency and management quality. Castle Biosciences, Inc. (CSTL) , Qifu Technology, Inc. (QFIN) , Euroseas Ltd. (ESEA) and Strategic Education, Inc. (STRA) boast solid net profit margins.Net Profit Margin = Net profit/Sales * 100.Net profit represents the a ...

Castle Biosciences, Inc. (CSTL) closed the last trading session at $28.87, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41 indicates a 42% upside potential.The average comprises nine short-term price targets ranging from a low of $32 to a high of $50, with a standard deviation of $5.22. While the lowest estimate indicates an increase of 10.8% from the current price ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Castle Biosciences, Inc. (CSTL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Confere ...

Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced earnings of $0.31, delivering a surprise of 293.75%.Over the last four quarter ...

Empowering people, informing care decisions ©2024 Castle Biosciences 1 Third Quarter 2024 November 4, 2024 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our position ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 Castle Biosciences Reports Third Quarter 2024 Results Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 4, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the th ...